The effect of renin-angiotensin blockers on COVID-19 related mortality: A tertiary center's experience
| dc.authorid | 0000-0001-6643-9364 | |
| dc.contributor.author | Oflar, Ersan | |
| dc.contributor.author | Koyuncu, Atilla | |
| dc.contributor.author | Alp, Murat Erdem | |
| dc.contributor.author | Kara Osmanoğlu, Hayat Kumbasar | |
| dc.contributor.author | Ünal, Orçun | |
| dc.contributor.author | Beyaz, Metin Onur | |
| dc.contributor.author | Öztaş, Didem Melis | |
| dc.contributor.author | Uğurlucan, Murat | |
| dc.contributor.author | Turhan Çağlar, Fatma Nihan | |
| dc.date.accessioned | 2022-08-05T08:50:33Z | |
| dc.date.available | 2022-08-05T08:50:33Z | |
| dc.date.issued | 2022 | |
| dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kalp ve Damar Cerrahisi Ana Bilim Dalı | |
| dc.description.abstract | Background: The first reports on coronaviruse disease 2019 (COVID-19) revealed an exaggerated mortality rate in hypertensive patients. In this regard, concerns about angiotensin-converting enzyme (ACE) inhibitors’ and angiotensin-receptor blockers’ (ARBs) have been aroused. Our aim in this study was to evaluate the potential bad outcome effect of hypertension and anti-hypertensive therapy on COVID-19. Methods: 183 patients with polymerase-chain-reaction (PCR)-proven COVID-19, who were admitted to our hospital and consulted to cardiology department between 15th of March and 15th of April 2020 were included. Data were recruited from hospital records. Results: Thirty-two out of 183 patients with COVID-19 died in hospital. Hypertension incidence was not statistically different between patients who survived and died (76 [50.3%] vs 19 [59.4%, p = 0.352]). Although the usage rate of ACEI were similar among groups, ARB usage rate was significantly higher in patients who died than survived (11 [34.4%] vs 23 [15.2%], p = 0.011). Binary regression analysis showed an association between ARBs and mortality (OR: 0.032, 95% CI 1.045–2.623, p = 0.032). Conclusion: Our study confirmed previous concerns regarding a potential harmful effects of ARBs on COVID-19 related mortality. | |
| dc.description.abstract | Kontext: První zprávy o onemocn?ní koronavirem v roce 2019 (coronavirus disease 2019, COVID-19) ukazovaly na zv?šenou mortalitu jedinc? s hypertenzí, co? vyvolalo obavy ohledn? u?ívání inhibitor? angiotenzin konvertujícího enzymu (ACEI) a blokátor? receptoru AT1 pro angiotenzin II (ARB). Cílem naší studie bylo posoudit mo?nost nep?íznivého vlivu onemocn?ní covid-19 na záva?nost hypertenze a ú?innost antihypertenzní lé?by. Metody: Do studie bylo za?azeno 183 pacient? s onemocn?ním covid-19 prokázan?m PCR testem, kte?í byli v období od 15. b?ezna do 15. dubna 2020 p?ijati do naší nemocnice a následn? odesláni na kardiologickou kliniku. Údaje byly získány z nemocni?ních záznam?. V?sledky: Celkem 32 ze 183 pacient? s onemocn?ním covid-19 zem?elo v nemocnici. Incidence hypertenze se mezi pacienty, kte?í p?e?ili a zem?eli, statisticky v?znamn? nelišila (76 [50,3 %] vs. 19 [59,4 %]; p = 0,352). I kdy? podíly pacient? u?ívajících inhibitory ACE byly v obou skupinách podobné, lé?iva ze skupiny ARB u?ívalo statisticky v?znamn? více pacient?, kte?í zem?eli, ne? t?ch, kte?í p?e?ili (11 [34,4 %] vs. 23 [15,2 %]; p = 0,011). Binární regresní anal?za prokázala souvislost mezi u?íváním ARB a mortalitou (OR: 0,032; 95% CI 1,045–2,623; p = 0,032). Záv?r: Naše studie potvrdila p?vodní obavy t?kající se mo?n?ch škodliv?ch ú?ink? lékové skupiny ARB na mortalitu v souvislosti v onemocn?ním covid-19. | |
| dc.identifier.citation | Oflar, E., Koyuncu, A., Alp, M. E., Kara Osmanoğlu, H. K., Ünal, O., Beyaz, M. O. ... Turhan Çağlar, F. N. (2022). The effect of renin-angiotensin blockers on COVID-19 related mortality: A tertiary center's experience. Cor et Vasa, 64(3), 277-281. https://doi.org/10.33678/cor.2021.123 | |
| dc.identifier.doi | 10.33678/cor.2021.123 | |
| dc.identifier.endpage | 281 | |
| dc.identifier.issn | 0010-8650 | |
| dc.identifier.issn | 1803-7712 | |
| dc.identifier.issue | 3 | |
| dc.identifier.scopus | 2-s2.0-85135095200 | |
| dc.identifier.scopusquality | Q4 | |
| dc.identifier.startpage | 277 | |
| dc.identifier.uri | https://doi.org/10.33678/cor.2021.123 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/9630 | |
| dc.identifier.volume | 64 | |
| dc.identifier.wos | 000826775300003 | en_US |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.institutionauthor | Uğurlucan, Murat | |
| dc.language.iso | en | |
| dc.publisher | Czech Society of Cardiology & Czech Society Cardiovascular Surgery | |
| dc.relation.ispartof | Cor et Vasa | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Angiotensin Converting Enzyme | |
| dc.subject | COVID-19 | |
| dc.subject | Pandemics | |
| dc.subject | Renin-Angiotensin | |
| dc.subject | Angiotensin Konvertující Enzym | |
| dc.subject | Covid-19 | |
| dc.subject | Pandemie | |
| dc.subject | Renin-Angiotenzin | |
| dc.title | The effect of renin-angiotensin blockers on COVID-19 related mortality: A tertiary center's experience | |
| dc.type | Article |
